Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taranabant Weight Loss Maintenance
NCT00420589Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of taranabant in obesity (4 arms), sponsored by Merck & Co. Primary endpoint: Body weight at 52 weeks. Started Oct 2006; status: terminated.
02
Drugs
taranabant
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00420589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00420589.